Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BerGenBio ASA logo — Developing Innovative Drugs for Aggressive Diseases

BerGenBio ASA

Developing Innovative Drugs for Aggressive Diseases

Founded 2008 Norway Norway 23 employees Post-IPO Debt Total: $1.50B Biotechnology, Pharmaceutical

General Information

Company Name BerGenBio ASA
Founded Year 2008
Location Norway Norway
Employees 23
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with BerGenBio ASA. To contact BerGenBio ASA, visit bergenbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BerGenBio ASA compare?

A PDF of BerGenBio ASA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BerGenBio ASA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Norway. The company is dedicated to developing innovative drugs for aggressive diseases. BerGenBio is focused on creating a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. They are globally recognized for their understanding of the central role of AXL kinase in promoting cancer spread, immune evasion, and drug resistance, which accounts for approximately 90 percent of cancer deaths. The company's approach to inhibiting AXL kinase activity provides a novel strategy to address a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering new therapeutic options for cancer patients. Post-IPO Debt investment of kr250.00M in November 2023 demonstrates the confidence in BerGenBio's approach and potential in the biotechnology and pharmaceutical industries.

Business keywords: biopharmaceutical, drug development, clinical-stage, cancer treatment, AXL kinase inhibitors, aggressive cancers, immune evasion, drug resistance, cancer research, therapeutic options, innovative drugs

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt kr250.00M -
30 Nov 2023
Post IPO Debt kr100.00M 1
Meteva AS
25 Oct 2022
Post IPO Equity kr500.00M -
05 May 2020
Post IPO Equity kr219.90M -
30 Jan 2020
Post IPO Equity kr187.50M -
13 Apr 2018
Series D kr212.00M 2
Investinor
Investinor, Meteva AS
18 Mar 2016
Series C $12.50M 2
Investinor Sarsia Seed Management
Investinor, Sarsia Seed Management
05 Feb 2014
Series B $6.00M 1
Investinor
Investinor
01 May 2013
Series A $8.80M 2
Investinor Sarsia Seed Management
Investinor, Sarsia Seed Management
09 Jan 2012
Seed Round $1.30M 2
Birk Venture Sarsia Seed Management
Birk Venture, Sarsia Seed Management
02 Mar 2011

BerGenBio ASA Alternatives & Competitors

View All Alternatives
BerGenBio ASA vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
BerGenBio ASA vs
Senex Biotechnology. Inc.
Senex Biotechnology. Inc.

Preventing Adaptive Drug Resistance and Cancer Metastasis

Debt Financing
5 employees
Biotechnology, Health and Wellness
BerGenBio ASA vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About BerGenBio ASA

Developing Innovative Drugs for Aggressive Diseases
BerGenBio ASA was founded in 2008.
BerGenBio ASA is headquartered in Norway.
BerGenBio ASA operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical, drug development, clinical-stage and cancer treatment.
BerGenBio ASA has approximately 23 employees.
BerGenBio ASA has completed 10 funding rounds, raising a total of $1.50B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to BerGenBio ASA include Prescient Therapeutics, Senex Biotechnology. Inc., Advenchen Laboratories, LLC, ORIC Pharmaceuticals Inc., Biond Biologics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BerGenBio ASA and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BerGenBio ASA, https://bouncewatch.com/company/bergenbio-asa, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout